Dong-A ST announced on the 18th that its autoimmune disease treatment, Immuldosa, received approval from the European Commission.
Immuldosa is a biosimilar of Stelara (generic name ustekinumab), developed by the pharmaceutical subsidiary Janssen of the global pharmaceutical company Johnson & Johnson. It inhibits the activity of interleukin (IL)-12 and 23, substances related to inflammation, and is prescribed for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Prior to this, it received approval from the U.S. Food and Drug Administration (FDA) in October. Immuldosa has been jointly developed by Dong-A Socio Holdings and Meiji Seika Pharma since 2013, and in 2020, the development and commercialization rights were transferred to Dong-A ST for efficient global business execution.
A Dong-A ST official said, "With the consecutive approvals in the U.S. and Europe, the entry of Immuldosa into the global pharmaceutical market is one step closer," and added, "We will do our best to ensure that Immuldosa becomes a viable treatment option for many patients in the global market."